NCT01569984View on ClinicalTrials.gov

Radiosensitization of AVASTIN® (Bevacizumab) With Stereotactic Body Radiotherapy for Colorectal Liver Metastasis

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Colorectal Cancer.
Interventions
RADIATION

Stereotactic body radiotherapy

Avastin 7.5 mg/kg IV x 2 doses 14 days apart

Trial Locations (1)

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

Dr. Yoo-Joung Ko

OTHER

NCT01569984 - Radiosensitization of AVASTIN® (Bevacizumab) With Stereotactic Body Radiotherapy for Colorectal Liver Metastasis | Biotech Hunter | Biotech Hunter